Glioblastoma stem cell-specific histamine secretion drives pro-angiogenic tumor microenvironment remodeling
Jiayi Chen,Guangqin Liu,Xinzheng Wang,Hao Hong,Tingting Li,Lin Li,Hongxiang Wang,Jiong Xie,Bohan Li,Ting Li,Dingyi Lu,Yakun Zhang,Haixin Zhao,Chengcheng Yao,Kaiqing Wen,Teng Li,Jing Chen,Shengming Wu,Kun He,Wei-Na Zhang,Jie Zhao,Na Wang,Qiuying Han,Qing Xia,Ji Qi,Juxiang Chen,Tao Zhou,Jianghong Man,Xue-Min Zhang,Ai-Ling Li,Xin Pan
DOI: https://doi.org/10.1016/j.stem.2022.09.009
IF: 23.9
2022-11-04
Cell Stem Cell
Abstract:The communication between glioblastoma stem cells (GSCs) and the surrounding microenvironment is a prominent feature accounting for the aggressive biology of glioblastoma multiforme (GBM). However, the mechanisms by which GSCs proactively drive interactions with microenvironment is not well understood. In this study, we interrogated metabolites that are preferentially secreted from GSCs and found that GSCs produce and secrete histamine to shape a pro-angiogenic tumor microenvironment. This histamine-producing ability is attributed to H3K4me3 modification-activated histidine decarboxylase (HDC) transcription via MYC. Notably, HDC is highly expressed in GBM, which is associated with poor survival of these patients. GSC-secreted histamine activates endothelial cells by triggering a histamine H1 receptor (H 1 R)-Ca 2+ -NF-κB axis, thereby promoting angiogenesis and GBM progression. Importantly, pharmacological blockage of H 1 R using antihistamines impedes the growth of GBM xenografts in mice. Our findings establish that GSC-specific metabolite secretion remodels the tumor microenvironment and highlight histamine targeting as a potential strategy for GBM therapy. Introduction Glioblastoma multiforme (GBM) is the most common and aggressive primary brain carcinoma in adults (Omuro, and DeAngelis, 2013 Omuro A. DeAngelis L.M. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013; 310 : 1842-1850 Crossref PubMed Scopus (1426) Google Scholar ; Shergalis et al., 2018 Shergalis A. Bankhead 3rd, A. Luesakul U. Muangsin N. Neamati N. Current challenges and opportunities in treating glioblastoma. Pharmacol. Rev. 2018; 70 : 412-445 Crossref PubMed Scopus (339) Google Scholar ). Even with optimal treatment (comprising surgery, radiotherapy, and chemotherapy), patients with GBM still have poor prognoses (Aldape et al., 2019 Aldape K. Brindle K.M. Chesler L. Chopra R. Gajjar A. Gilbert M.R. Gottardo N. Gutmann D.H. Hargrave D. Holland E.C. et al. Challenges to curing primary brain tumours. Nat. Rev. Clin. Oncol. 2019; 16 : 509-520 Crossref PubMed Scopus (314) Google Scholar ). GBM contains an aggressive population of tumor cells known as glioblastoma stem cells (GSCs) due to their stem-like properties (Singh et al., 2004 Singh S.K. Hawkins C. Clarke I.D. Squire J.A. Bayani J. Hide T. Henkelman R.M. Cusimano M.D. Dirks P.B. Identification of human brain tumour initiating cells. Nature. 2004; 432 : 396-401 Crossref PubMed Scopus (5994) Google Scholar ; Vescovi et al., 2006 Vescovi A.L. Galli R. Reynolds B.A. Brain tumour stem cells. Nat. Rev. Cancer. 2006; 6 : 425-436 Crossref PubMed</l -Abstract Truncated-
cell biology,cell & tissue engineering